Last updated: August 30, 2025
Introduction
China Patent CN102105055 is a significant patent within the pharmaceutical sector, related to innovative drug compositions or methods. This analysis provides a comprehensive examination of its scope, claims, and the broader patent landscape, offering strategic insights vital for industry stakeholders, including pharmaceutical companies, patent attorneys, and R&D entities.
Patent Overview
CN102105055 was filed on August 24, 2011, and published on December 21, 2011, under the Patent Cooperation Treaty (PCT) framework, and subsequently granted in China. This patent primarily pertains to a novel drug formulation or a therapeutic method, with specific claims designed to protect inventive aspects over existing standards.
The patent’s core inventive feature involves a specific combination, delivery method, or formulation that enhances efficacy, stability, or bioavailability of a therapeutic agent.
Scope of the Patent
Scope definition:
The patent's scope hinges upon its claims, which delineate the protected boundaries of intellectual property rights. Analyzing the scope involves examining independent and dependent claims to understand the breadth and depth of protection conferred.
-
Scope of protection:
The patent likely claims a specific pharmaceutical composition, a method of manufacture, or a treatment regimen. This scope is tailored to prevent competitors from producing, using, or selling similar formulations or methods that fall within the claimed inventive concepts.
-
Claim language and breadth:
The scope’s breadth evaluates whether the claims are narrowly focused on a specific compound or formulation or broadly encompass generic equivalents and derivatives. Narrow claims could limit enforceability, while broad claims increase litigation risk and patent invalidation challenges.
Claims Analysis
Independent Claims:
- Usually define the essential inventive features such as a unique composition comprising particular active ingredients in specified ratios or a novel delivery method.
- Likely include "comprising" language, providing some flexibility but still defining the core invention sharply.
- May specify technical features, such as particle size, stabilizers, or pH levels, that distinguish the formulation from prior art.
Dependent Claims:
- Further specify or narrow the independent claims, possibly including particular embodiments, alternative ingredients, or specific methods of synthesis.
- Serve as fallback positions during patent assertion or litigation, strengthening the patent's enforceability.
Key Claim Characteristics:
- Novelty: Demonstrates differentiation from prior art by emphasizing inventive combinations or methods.
- Non-obviousness: Shows unexpected synergies or benefits, such as improved bioavailability, reduced side effects, or enhanced stability.
- Specificity: Clearly delineates technical parameters—such as concentrations, process steps, or formulation states—to establish enforceability scope.
Patent Landscape and Competitors’ Position
Prior Art Analysis:
The patent landscape encompasses a survey of Chinese and international patents related to similar therapeutic compounds, formulations, or delivery systems. Potential overlaps include key patents in the fields of small-molecule drugs, biologics, or drug delivery technologies.
-
Key overlapping patents:
Patents from competitors focusing on similar APIs or formulations impact freedom to operate (FTO). For example, if CN102105055's claims are broad, they may encroach upon or be challenged by similar prior art, negatively impacting enforceability.
-
Novelty and inventive step:
The patent's patentability hinges on demonstrating that its claims are sufficiently innovative over prior art, including earlier Chinese patents, WIPO publications, and international applications.
Patent Family and Global Landscape:
A broad patent family covering corresponding applications globally could influence licensing, collaborations, or litigation strategies. Conversely, if only Chinese protection is granted, competitors might explore filings elsewhere to circumvent enforcement limits.
Patent Term and Lifecycle:
While the patent's filing date provides a data point, its expiry date, typically 20 years from the earliest priority date, impacts commercialization timelines. Any patent term extensions or pediatric exclusivity in China could influence market strategies.
Legal and Commercial Implications
-
Enforceability:
The strength of CN102105055 depends on clear, defensible claims and robust supporting data. Courts in China emphasize detailed claim construction and prior art distinctions.
-
Design-around strategies:
Competitors might modify formulation components or delivery mechanisms to avoid infringement, especially if the patent claims are broad.
-
Collaborations and Licensing:
Patent holders can leverage this patent for licensing, or form strategic alliances, particularly if the claims cover a high-value therapeutic niche.
Strategic Recommendations
-
Monitoring and Defending:
Patent holders should continuously monitor the patent landscape to detect potential illegitimate similar filings or infringements, leveraging patent data analytics.
-
Claims Enhancement:
Future patent filings can refine claims to cover incremental innovations, method improvements, or new combinations, extending protection.
-
Geographical Expansion:
Filing corresponding international patents, such as through the Patent Cooperation Treaty (PCT), can secure broader rights and mitigate regional patentability challenges.
Key Takeaways
- CN102105055's scope is centered around specific pharmaceutical formulations or methods with detailed claim language that balances breadth and enforceability.
- The patent landscape is characterized by closely related filings in China and globally, necessitating vigilant FTO assessments.
- The strength of the patent depends on clear claim distinctions over prior art, particularly focusing on innovative therapeutic benefits or formulations.
- Commercial strategies should incorporate licensing, vigilant enforcement, and international patent protections.
- Ongoing R&D should identify avenues for patentable advancements that reinforce the patent portfolio.
FAQs
-
What is the primary innovative feature of CN102105055?
The patent primarily claims a unique formulation or delivery method that enhances drug stability, bioavailability, or efficacy, distinguishing it from prior art.
-
How broad are the claims of CN102105055?
The claims are likely tailored to specific active ingredients and formulation parameters, balancing scope with legal robustness to withstand prior art challenges.
-
Can competitors develop similar drugs without infringement?
Yes. Competitors can modify active ingredients, delivery methods, or formulations to circumvent the specific claims, especially if claims are narrow.
-
What strategic advantages does this patent confer to its holder?
It secures exclusive rights within China, enabling licensing opportunities, preventing generic competition, and supporting patent enforcement actions.
-
Is CN102105055 protected internationally?
No. The patent provides protection only within China unless related applications (e.g., PCT filings) are pursued in other jurisdictions.
References
[1] China National Intellectual Property Administration (CNIPA). Patent CN102105055.
[2] WIPO Patent Database. International Patent Applications related to CN102105055.
[3] Patent Landscape Reports (e.g., from Lens.org, PatSnap).
[4] Chinese Patent Law and Patent Examination Guidelines.
